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ABSTRACT

and causing severe disease in populations that
were thought to be at low risk. This narrative

Clostridium difficile infection (CDI) was once
considered a primarily nosocomial concern.

review summarises potential pathways for
infection outside of the hospital environment

Emerging evidence from the last 20 years has

and highlights likely routes of transmission.

highlighted a drastic shift in the known
epidemiology of CDI, with disease outside of

Further, evidence is presented on potential risk
factors
for
development
of
disease.

hospitals apparently occurring more frequently

Understanding the epidemiology of CDI
outside of hospitals is essential to the ability
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to prevent and control disease in vulnerable
populations.

Keywords: Animal reservoir/source; Clostridium
difficile infection (CDI); Community-associated
CDI; Epidemiology; Risk factors

INTRODUCTION
Clostridium

difficile

is

a

spore-forming,

gram-positive, anaerobic bacillus, which is a
frequent
cause
of
antibiotic-associated
diarrhoea, especially amongst hospitalised
patients [1, 2]. The spectrum of disease caused
by C. difficile infection (CDI) can range from
mild diarrhoea to severe conditions such as
fulminant colitis and toxic megacolon resulting
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in death [1, 3]. In 2010, the Society of

These resulted in misclassification due to a

Healthcare Epidemiology of America (SHEA)

failure to determine hospitalisation history in

identified the epidemiology, pathogenesis,
treatment and prevention of infection with C.

cases presenting from the community [14].
Recommended standard case definitions

difficile as one of the five most important
clinical challenges facing the discipline of

were published by the European Society of
Clinical Microbiology and Infectious Diseases

Healthcare Epidemiology [4].

(ESCMID) Study Group for C. difficile in 2006

Historically, CDI was considered largely
nosocomial, with exogenous acquisition from

[15] and, in early 2007, the Centers for Disease
Control and Prevention (CDC) ad hoc C. difficile

the healthcare environment considered the
main source of colonisation or infection [5].

working group recommended similar case
definitions [16]. These definitions have had

The capacity of C. difficile to cause disease in the

wide acceptance and are commonly used to

community was reportedly recognised as early
as 1982 [6], although this disease was still

categorise cases into HA or CA. The definitions
take
into
account
the
clinical
and

considered rare in this population only
20 years ago [7, 8]. This article examines the

microbiological evidence to establish what a
‘case’ of CDI is and further elucidate whether a

literature on community-associated (CA) CDI

case should be classified as HA or CA. A

and the emergence of C. difficile as a cause of
significant disease outside of healthcare

summary of the accepted case definitions of
CA- and HA-CDI is shown in Table 1.

settings. Suggested routes of transmission,
including
human,
animal,
food
and

The CDC working group noted that these
definitions
were
‘‘interim
surveillance

environmental
Understanding

definitions and recommendations based on
existing literature and expert opinion that can

sources,
are
the
interaction

explored.
between

hospital and community cases is paramount in

help

determining the underlying drivers behind the
apparent global increase in cases of CA-CDI.

prevention efforts’’ [16]. Although these were
published as ‘interim’ definitions, they have not

to

improve

CDAD

surveillance

and

This article is based on previously conducted
studies and does not involve any new studies of

been updated since their release in 2007. The
recently updated European Centre for Disease

human or animal subjects performed by any of

Prevention and Control (ECDC) C. difficile

the authors. Ethics approval was not required
for this narrative review.

surveillance protocol has not altered these
original definitions [17].

Healthcare-associated vs.

It is likely that current enhanced surveillance
definitions can be improved. Current enhanced

community-associated infection

surveillance definitions attribute a case to a
considered

healthcare facility exposure if it occurred within
4 weeks of discharge and provided the case was

healthcare-associated (HA)- vs. CA-CDI is
essential in determining the validity of case

in hospital for a minimum of 48 h (HAI CO)
[15, 16]. There are several limitations with this

classifications. Prior to an agreed definition of
what
‘community-associated’
infection

definition. The necessary minimum 48 h stay as

Defining

what

is

entailed, non-standardised definitions were

an inpatient prior to diagnosis for an infection
to be considered potentially HA may not be

applied by a number of authors [7, 9–13].

necessary, as prolonged exposure to C. difficile is
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Table 1 Clostridium difﬁcile-enhanced surveillance deﬁnitions (Source: McDonald et al. [16])
Classiﬁcation

Deﬁnition

1. Healthcare facility onset, healthcare
facility-associated infection (HO-HCFA)

A case with symptom onset more than 48 h after hospital admission

2. Community onset, healthcare
facility-associated infection (CO-HCFA)

A case with symptom onset in the community or 48 h or less after
admission to an HCF, provided that symptom onset was less than
4 weeks after the last discharge from an HCF. Community-onset,
HCF-associated cases should be attributed to the HCF from which the
patient was last discharged, providing the patient was an inpatient of
that HCF for more than 48 h

3. Community-associated Clostridium
difﬁcile-associated disease (CA-CDAD)

A case with symptom onset in the community or 48 h or less after
admission to an HCF, provided that symptom onset was more than
12 weeks after the last discharge from an HCF

4. Indeterminate

A case who does not ﬁt any of the above criteria for an exposure setting,
e.g. a patient who has symptom onset in the community but who was
discharged from the same or another HCF 4–12 weeks before
symptom onset

5. Unknown

A case for whom the exposure setting cannot be determined because of
lack of available data

not required for infection, and potential sources

‘hospital in the home’ (HITH) patients, who

of acquisition should be assessed in light of
what is probable, possible or unlikely. Further

are provided hospital care via in-home medical
visits, however are considered ‘inpatients’ of the

evidence is needed to determine whether this

hospital for this period for the reporting of bed

minimum 48 h stay may be resulting in
misclassification of HAI CO cases as CAI cases.

days, and often in the reporting of other HA
infections
(i.e.
central
line-associated

Some patients frequently visit the hospital
for day procedures (e.g. chemotherapy and

bloodstream infections). While considered
inpatients for reporting purposes, these cases

dialysis) and, as a result, have not had a

reside in their home for the duration of their

length of stay more than 48 h prior to
diagnosis. With frequent contact with the

treatment, and therefore acquisition of the
infection has occurred outside of the hospital

hospital environment (which previous studies
have shown can be contaminated with C.

setting. HITH patients should not be considered
inpatients for the purposes of surveillance, and

difficile spores [18]) up to 3–4 times per week,

infections

ruling out the hospital as a source of acquisition
may result in misclassification.

should be classified CAI.
In addition, there

There are other circumstances under which
application
of
the
current
enhanced

concerning the number of HAI HCFO cases
who may have been colonised on admission to

surveillance definitions may be more likely to
result in misclassification. One group is

hospital and only developed disease after being
exposed to antimicrobials as part of their

occurring

in

these
is

populations

little

evidence
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medical management. The rates of colonisation

strains

in ‘healthy individuals’ in the community are

non-toxigenic strains. To account for variable

relatively low [19, 20]; recent data from a
Canadian study suggest approximately 5% of

positive predictive values (PPVs) in populations
with low prevalence, both ESCMID and the

patients admitted to hospital may be
asymptomatically colonised [21]; however it is

CDC recommend a two-step testing process,
with a sensitive screening test as the first test

not clear how much this may vary across

[24,

different regions. The work of Eyre and
colleagues on over 1200 hospital cases of C.

suitable under all circumstances, and the
outcome (e.g. diagnosis of infection, public

difficile over a 3.6-year period found that only
35% of cases were genetically related to at least

health surveillance) must be taken into
account when performing diagnostic testing.

25].

and

which

Currently,

are

no

harbouring

single

test

is

one previous case [22]. These data support the
hypothesis that asymptomatic colonisation on
admission to a HCF has a significant impact on
case numbers, even on those deemed HAI
HCFO.

THE EMERGENCE
OF COMMUNITY-ASSOCIATED CDI
The emergence of, and risk factors for, CA-CDI
have become major areas for research
internationally
[26–28].
Most
literature
focusing on CDI epidemiology is based on

LABORATORY TESTING
FOR CLOSTRIDIUM DIFFICILE
INFECTION

hospital

data.

Given

the

relatively

high

by

proportions of disease and risk factors within
this population, this is not unexpected.

laboratories have been highlighted as an area
of concern when estimates of CDI prevalence

Epidemiological studies of CA-CDI often
include cases that have been detected at a

are being conducted across multiple sites or

healthcare facility. This undoubtedly skews the

countries [23]. Several diagnostic tests are
available for CDI. There are advantages and

data, as hospital-identified (HI)-CDI may be
more severe (i.e., severe enough to warrant

disadvantages of various testing methods, often
with trade-offs among sensitivity, specificity,

presentation at a hospital for treatment) and
under-represented, as an acute care facility is

turn-around time and costs. The available tests

likely not the primary source of healthcare for

can loosely be grouped into those that detect
the organism, those that detect the toxin and

many people living in the community who
develop gastroenteritis symptoms.

those that determine whether the organism is
potentially capable of producing toxin by

The reported incidence of CA-CDI is likely to
vary based on the study population and local

detecting toxin genes. A summary of the

awareness and testing practices. Hospital-based

various testing methods is shown in Table 2.
The ability of different tests to detect

studies looking at cases of CA-CDI are
suitable to compare prevalence across different

different targets will clearly limit the ability of
some studies to correctly determine which

regions, as this allows determination of the
proportion of CA disease in populations

patients have active disease, which are
asymptomatically colonised with toxigenic

presenting to acute care facilities. This method
is more reliable than trying to determine the

Different

diagnostic

techniques

used
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Table 2 Diagnostic methods for the detection of C. difﬁcile (adapted from Rupnik et al. [26])
Diagnostic method

Advantages

Disadvantages

Culture

Sensitive

Does not differentiate toxigenic and non-toxigenic
strains
Slow

Antigen detection (glutamate
dehydrogenase [GDH])

High negative
predictive value

Non-speciﬁc (requires supplementary testing)

Fast
Cytotoxin assay

Sensitive

Slow

High speciﬁcity for
infection
Enzyme immunoassay

Fast

Low positive predictive value, particularly in population
with low prevalence

Membrane assays

Fast

Low positive predictive value, particularly in population
with low prevalence

Real-time PCR

Rapid

Uncertain speciﬁcity for infection

Toxigenic culture

High sensitivity

Uncertain speciﬁcity for infection
Slow

Toxin B gene detection

High sensitivity

Uncertain speciﬁcity for infection

Fast

High cost

relative incidence in a community, with
methodological difficulties in determining
catchment populations and testing often at

suggesting a potential source of infection in the
community.
Using

a

90-day

cut

point

for

recent

the discretion of the referring physician [29],
which may lead to under-reporting.

hospitalisation to define a case of ‘probable
community-acquired CDI’, a study using

Europe

administrative data in the England over a
12-year period demonstrated an increase in
both the rate and proportion of CAI [33]. The

Under-diagnosis of CDI, particularly among
community cases, has been noted in Europe

overall
proportion
community-acquired CDI

[30, 31]. This may be owing to lack of clinical
awareness
or
non-sensitive
laboratory

increased from 7.1% to 13.5%. Consistent
application of the same definition for

diagnostic tests [30]. Early reports showed that
even when CA-CDI was considered relatively

surveillance

purposes

is

of
in

probable
this study

sufficient

to

uncommon, cases were being identified in

demonstrate a real increase over time.
A recent multi-centre study across

individuals with no recent hospitalisation
history or links to outbreaks in hospitals [32],

hospitals in 34 European countries applied
enhanced surveillance criteria to 506 CDI cases

97
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and found 70/506 (14%) of cases were classified

conducted

CA-CDI [34]. The proportion of CA-CDI varied

Singapore-based, single-centre study found an

in

these

regions.

A

recent

markedly across countries, ranging from 0% to
82%. As this was a hospital-based study, it is

overall prevalence of 13.6% CA-CDI [41], lower
than rates reported in other regions but

difficult to assess whether the patient
population and testing practices had a major

nonetheless reflective of CA disease being of
concern in this region. A comprehensive study

influence on rates from the limited information

of CDI in all Australian jurisdictions was

available.

published in 2014, although CA case data were
not available for all geographical areas [42].

North America

From the data contributed by three states,
Tasmania, Victoria and Western Australia,

While CA-CDI is increasingly recognised in the
USA, under-reporting is still suspected [35].

CA-CDI comprised 26% of all HI-CDI cases

Some large-scale CA-CDI studies have been

between 2010 and 2012 [42].
One
Kuwait-based
study

investigated

undertaken in the USA. A six-centre study in
North Carolina published in 2010 reported a

diarrhoea in 2584 outpatients [43]. Although
this study was not set up to determine the

prevalence of CA-CDI of 20% [36]. In another
multi-centre US study involving eight

proportions of CA-CDI and HA-CDI, 16 cases

the

were identified over a 2-year period, none of
which had been hospitalised in the previous

reported prevalence of CA-CDI was 32% [37].
A further important finding of this study was

6 months [43]. These data suggest a low
prevalence of CA-CDI (0.62%) presenting to

that one in four patients with CA-CDI was
hospitalised within 7 days of diagnosis,

this particular facility. There are few data from
South America or Africa describing CA-CDI. It is

representing a significant cost and burden to
the healthcare system. Others have reported

unclear whether CDI represents a smaller

geographic

areas

and

10,342

cases,

even higher rates of hospitalisation (up to 40%)

burden of disease in these regions, and there is
a lack of public health awareness around the

in CA-CDI cases [38].
Allard and colleagues surveyed 15 hospitals

disease and a lower priority in terms of public
health surveillance and activity or a

in Montreal 2005–2006 and, of 2297 cases of
CDI, 599 (27%) were classified as CA-CDI, at a

combination of these and other factors.

rate of 32 cases per 100,000 person-years [39].
Similar rates were observed across one reporting
year in another Canadian province (Manitoba)

RISK FACTORS
FOR COMMUNITY-ASSOCIATED
CDI

by Lambert and colleagues, who also reported a
prevalence of 27% and a rate of 23.4 cases per

There are several established risk factors for

100,000 person-years [40].

CA-CDI. There are some similarities and
differences between risk factors in CA and HA

Other Regions

cases [44]. For HA-CDI, advanced age ([65),
antibiotic treatment and co-morbidities are all

There are few studies on CA-CDI outside of

recognised risk factors [45, 46]. CA-CDI, on the
other hand, is frequently documented as

North America and Europe, perhaps reflecting
an overall lack of C. difficile studies in general

occurring in younger populations who lack

Infect Dis Ther (2016) 5:231–251
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[27, 47–51].

compared to HA-CDI cases had no previous

Susceptibility to infection to some extent

antibiotic exposure [61–64]. Thus antibiotics

appears to vary on a case-by-case basis; while
some CA-CDI cases may have many established

have an important, but perhaps not essential,
role in CA-CDI, and other yet to be determined

risk factors, others seemingly lack the most
important exposures, reflecting our lack of

factors may play a role. Healthcare providers in
the community should be cognisant of

understanding of this entity. The degree to

potential for CDI cases presenting with no

which host factors influence susceptibility and
outcomes in disease is still not clear at this

prior history
hospitalisation.

stage. Building a risk profile for CA-CDI may
assist primary care providers in identifying

Several studies have examined the use of
gastric acid suppressants and their relationship

these

traditional risk factors

of

antimicrobial

use

or

these cases in the community setting.

with CDI [60, 65–67], with varying estimates of

Antibiotics and Gastric Acid Suppressants

risk for CA-CDI (including nil significant
findings) [68]. The use of PPIs appears to be

Antibiotic exposure is the most important risk

particularly significant for the subset of CA-CDI
that is not associated with prior antimicrobial

factor for all CDI, including CA-CDI
[13, 36, 52–55]. While a meta-analysis

exposure [60], indicating that the disruption to

conducted in the USA, focusing on CA-CDI

the microbiota, which occurs following
exposure to a PPI [69–71], may be sufficient to

and antibiotics, supported recent antibiotic
exposure being an important risk factor for

cause disease in the absence of antimicrobial
therapy.

developing CA-CDI [56], this was not uniform
for
all
antimicrobials.
Certain
classes

Co-morbidities

(clindamycin,
fluoroquinolones
and
cephalosporins) presented the most significant

CDI is a significant problem in populations with

risk, and others (e.g. tetracyclines) had no

inflammatory bowel disease (IBD) (including

associated increased risk [56]. The discrepant
risk associated with different classes of

Crohn’s disease), with a high incidence, severe
disease and evidence of increasing rates over

antimicrobials has been found by
researchers [7, 57]. A case-control

other
study

time [72–74]. As patients with a flare in their
IBD have diarrhoea, this leaves open the

conducted in the UK also found that exposure

possibility that this is being detected more in

to antibiotics in the previous 4 weeks,
particularly multiple agents, was significantly

this group because of surveillance bias [48]. This
is especially true among Crohn’s patients, half

more frequent among CA-CDI cases than
controls [58].

of whom do not have colonic involvement in
disease [75]. This is, however, unlikely to

Although an important risk factor, US

account for all of the recent increases in

studies on CA-CDI cases have found 32–36%
of those with a documented medication history

disease observed in IBD cases, with IBD
patients appearing to have a different

had no previous antibiotic exposure in the
preceding
3 months
[59,
60].
Further

acquisition
pattern
from
the
general
population, including increased susceptibility

international
proportions

studies

have

shown

larger

to a wider range of sources in the community

(43–65%)

of

CA-CDI

cases

[76]. There may also be an additional problem
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in that not all patients with an apparent flare in

hypothesis was offered for this discrepancy.

their IBD are being tested for CDI, leading to

CA-CDI has also been described in increasing

possible under-reporting of the problem.
Other co-morbid conditions are associated

numbers of peripartum women, many of whom
do not have any other predisposing factors

with increased risk of CA-CDI, including
chronic kidney disease, immunodeficiency

[87, 88]. Contact with infants B2 years old is
significantly
associated
with
CA-CDI

(through infection or drug therapy), malignant

[43, 58, 60], and children have been previously

lesions and solid organ transplants [27, 77, 78].
Severe co-morbid conditions such as these

identified as potential reservoirs in the
community [89]. As the usual primary care

increase the risk of CDI because of prolonged
use of antimicrobials and frequent contact with

givers for neonates and young infants, the
possibility that neonates are responsible for

healthcare facilities [27]. As current definitions

causing disease in women in the community

require an inpatient stay of [48 h prior to
diagnosis in order to classify an infection as

warrants further investigation.

HAI, frequent, short-stay hospital visits (such as
those for dialysis or chemotherapy) may not be

TRANSMISSION OF CDI
IN THE COMMUNITY

captured in this determination.
As C. difficile has traditionally been treated as a
nosocomial infection, much of the literature

Contact with Children <2 Years of Age

around transmission focuses on the hospital
Identification of C. difficile from neonates has
been long established; the first isolation of this
organism in 1935 was from the stool of healthy
infants [79]. Although relatively rare in healthy
adults,
asymptomatic
colonisation
with
toxigenic C. difficile occurs commonly among
neonates and children \2 years old [80–82].
Acquisition can either occur during the
neonatal period or later on (between 4 and
6 months of age), which corresponds to the
weaning

period

[80].

Risk

factors

for

development of disease in children \2 years
appear to differ from the rest of the population
[83] and, as previously noted, true disease as
opposed to concurrent carriage in diarrhoeal
patients may be difficult to discern. More
research is required to determine the scope of
magnitude of CDI in this population [84].
CA-CDI occurs more frequently in females
than males [85, 86]. A 2006 study conducted in

environment, extending into long-term and
similar care facilities. The recognition of this
organism as a cause of diarrhoeal illness in the
community has driven more recent research
efforts towards understanding the acquisition
and transmission of C. difficile outside of the
hospital setting.
In 2010, Otten and colleagues published a
transmission model of CA-CDI as an initial step
towards developing a risk assessment for this
pathogen in the community [90]. The model
contain eight infection states: susceptible,
gastrointestinal exposure, colonised, diseased,
deceased, clinically resolved colonised, relapse
diseased and cleared, with directional transfers
between the states (Fig. 1). The model
represents a complex relationship between
epidemiological states in which a susceptible
individual lacking protective factors becomes

Connecticut found females had nearly twice the

exposed to the organism, which in some cases
leads to a diseased state. Sources of exposure

incidence of CA-CDI as males [59], although no

and risk factors for developing disease once

Infect Dis Ther (2016) 5:231–251
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Fig. 1 Transmission model of community-associated C. difﬁcile. Otten et al. [90]. Reproduced with permission
exposed are key areas for public health
intervention in order to prevent disease and

relatively common, with Alam and colleagues
finding an overall prevalence of 32.3% in

halt transmission.

household samples [91]. Toxigenic C. difficile

Potential sources of exposure in the
community are discussed in greater details

has been found on boots/shoes [91], which
suggests an introduction from contaminated

below, but can be categorised broadly into
consumption (ingestion of spores from a

soil from outside the home. Presence of spores
on kitchen surfaces and refrigerators [92] may

contaminated food product), person-to-person

indicate transfer from food products. If the data

contact (transmission from another infected or
colonised person), animal-to-person contact

collected to date on household contamination
are representative of a typical household,

(transmission from an infected or colonised
domestic
or
wild
animal)
and

people may expect to come into contact with
C. difficile in their home environments on a

environment-to-person contact (ingestion of

regular basis.

spores after exposure
environmental source).

The many reports on C. difficile outside of the
hospital environment demonstrate that this

to

a

contaminated

Environment

organism is ubiquitous in natural settings,
including soils [93–95] and waterways [93, 96],
and inevitably present in environments where

C. difficile contamination of households, even
excluding those of known cases, appears to be

human faecal matter is treated such as waste
water treatment plants [97, 98]. In addition,
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treated

animal

effluent

used

to

irrigate

colitis

have

long

been

therapy

in

associated

with

animals

[108].

agricultural products, and animal manure used

antimicrobial

for fertiliser, are other potential environmental
sources [99, 100], with treatment practices not

Outbreaks of CDI have been reported at
veterinary hospitals, affecting hospitalised

sufficient to eliminate the spores from the end
product. Thus, there are large numbers of

dogs [109].
This opens the possibility of C. difficile

potential environmental sources for CA-CDI.

sources for human infection in production

Highly discriminatory typing methods may
help to narrow down potential local

(food) animals, companion animals and
native/wild animals. As in neonatal humans,

environmental sources, including assessment
of the ability of water treatment processes to

many young animals are colonised by C.
difficile, which is displaced as the microflora

remove spores and prevent further spread in the

matures [110]. Unlike humans, neonatal piglets

environment.
The significance of finding low absolute

develop severe diseases including diarrhoea and
respiratory distress and demonstrated high

counts of C. difficile in environmental samples
is unclear—while the ‘infectious dose’ remains

levels of morbidity and mortality [110–112].
C. difficile has been documented in both

unknown, detection in any number of sources

healthy and diseased animals [113]. Recovery

may or may not be of public health significance
[100]. It is likely that people are coming into

methods may account for variation in
prevalence across studies [114, 115]. The

regular contact with a small number of C.
difficile either inside or outside of their home,

diseased status, age and species of animal also
influence
the
reported
prevalence

which are rarely capable of causing disease
unless
the
individual
has
a
highly

[113, 116–118]. Production (food) animals are
a widely studied group with C. difficile isolated

compromised gut flora. Discrepant individual

from pigs, cattle and poultry [115].

practices around hand hygiene, particularly
through hand washing before eating, may also

In North America, CDI is now considered the
most significant cause of neonatal diarrhoea in

impact on the significance of environmental
contamination and the possibility of disease

swine [119]. Production
historically
been
given

development.

antimicrobials

Animals

prophylactic measure for infectious disease
and as a growth promoters [120, 121]. The use

One potential source of C. difficile transmission

of antimicrobials alters the microflora in
livestock as it does in humans, leaving them

outside of the hospital environment is via
animals. Although many clostridia cause

mixed

in

animals have
broad-spectrum
with

feed

as

a

susceptible to CDI. Once the organism is

disease in both humans and animals, these

introduced to a herd, a large number of
susceptible animals living in close quarters can

have not traditionally been considered zoonotic
agents [101]. Molecular studies have, however,

rapidly become infected. CDI in production
animals is of concern to industry because of

demonstrated common C. difficile isolates in
production animals, companion animals and

potential growth delays in infected herds [122],

humans [102–107], particularly ribotype (RT)

loss of stock [123] and potential contamination
of meat and dairy products, which may damage

078. As in humans, diarrhoea and C. difficile

consumer confidence.
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Piglets can become colonised within an hour

prevalent among animals, are now causing

of birth, in the absence on antimicrobial

disease in increasing numbers in humans

treatment
extensive

[104, 106] implies that transmission
occurring from animals to humans.

[124], perhaps
environmental

a

reflection of
contamination.

is

Keessen
and
colleagues
demonstrated
widespread aerial dissemination of C. difficile

While animal-human or human-animal
transmission is biologically plausible, a

on

activity

common source in the environment that

contributing to an increase in numbers [125].
While the consequences of these findings for

allows transmission to both groups is an
equally valid suggestion. The ubiquity of C.

human health are not clear, detection of C.
difficile occurred 20 m from the facility that

difficile in the environment supports this
hypothesis. In the case of wild animal

raises the potential for wider contamination of

populations, it seems more plausible that the

the surrounding environment.
Common strains are reported in both animal

presence in these animals is indicative of C.
difficile present in the environment (e.g. via

populations and human isolates within the
same geographical region [126–128]. Common

contamination from treated waste) rather than
a route of human-animal transmission [133].

strains being found in both humans and

In order to establish C. difficile as a zoonotic

production animals leaves open the possibility
that transmission is occurring from human to

organism,
research
must
establish
an
epidemiological link between animals and

animal rather than the alternative. A small
study conducted by Keessen and colleagues

humans who do not share a common
environment that may be a common source of

among pig farm workers found daily to weekly
contact with pigs vs. monthly to less than

infection. The most likely scenario in which this
could occur is via the food chain or via water

yearly contact was significantly associated with

systems contaminated with the excrement of

an intestinal presence of C. difficile (p = 0.003)
[129]. These data support the alternative

colonised or infected animals. Monitoring the
prevalence of C. difficile in animal populations

hypothesis, with workers more likely to be
colonised via frequent contact with the

is useful in veterinary medicine and may further
inform decisions on the use of antimicrobials in

animals and their environment.

this

In addition, the organism has been isolated
from companion animals [130–132] and their

analysis of predominant strains in animals is
required to establish links with changes to

role as a reservoir of infection also requires
further investigation. Wild (native) animals

strains causing disease in human populations.

have been investigated and may play a role

Food

spreading C. difficile in the environment
[133, 134]. The detection of C. difficile in

The potential for C. difficile to act as a foodborne

animal populations and the similarities
between strains found in both humans and

pathogen undoubtedly exists, with several
authors examining this potential link. The

animals

majority of studies have focussed on retail
meats, especially beef, pork and poultry

a

pig

farm,

[126,

with

128]

personnel

are

suggestive

that

transmission between humans and animals is
occurring, either directly or indirectly. Evidence
that certain RTs such as RT 078, which are

population.

[135–139].

Moreover,

Presumably

the

longitudinal

detection

of

genetically similar strains in animal herds and
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humans has led to an increased awareness of the

gastrointestinal pathogen, exposure to the

potential

foodborne

organism, even in a large group of people,

pathogen. The potential for secondary
contamination of vegetables, e.g. onions and

may not result in many or even one case of
infection.

salads, has been explored to a lesser extent,
despite early evidence of these foods as a

With foodborne pathogens, the infectious
dose is of interest. This has not been established

potential source [93].

for C. difficile, and indeed it is not clear if there

RTs 078 and 027 have dominated meat
prevalence
surveys
in
North
America

is a minimum infectious dose required for a
susceptible host [100]. If this is the case, then

[135, 140–142]. This aligns with the common
RTs from animal studies and suggests that meat

even very low levels of contamination may be
sufficient of cause disease. Weese and colleagues

is being contaminated at some point in

noted all samples of retail chicken that

processing rather than from another external
source. Although not all RTs were able to be

contained C. difficile were only positive on
enrichment culture [142]; other studies that

matched to reference laboratory samples,
matches between RTs found in food samples

used detection methods with lower sensitivity
may have under-reported the prevalence.

and local human cases have been reported

Further,

[137, 143, 144]. A lack of standard typing
information across all studies highlights

contamination has been suggested as a
potential explanation for evidence of C.

current inadequacies in nomenclature in the
international literature and the impact this can

difficile in food products [147], which can be
dealt with by future researchers with the

have on identifying significant strains across
regions.

inclusion of additional highly discriminatory
techniques, such as whole-genome sequencing.

for

C.

difficile

as

a

the

possibility

of

laboratory

on

More evidence is required to provide an

ready-to-eat foods including meat and
vegetables as well as the demonstrated potential

epidemiological link between the consumption
of contaminated food and the development of

for spores to survive freezing and cooking
processes [145, 146] suggests that ingestion of

CDI and to establish whether foodborne
transmission occurs in the community at a

spores from contaminated food products and

frequency to cause public health concern.

subsequent infection of a susceptible host is a
plausible scenario. In addition, ribotyping data

However, the public health implications and
actions required are unclear; if any level of

show common strains in human and animal
infection
[126,
128]
although
further

exposure in the community might be enough
to precipitate disease development, then

whole-genome sequencing will be required to

prevention needs to be directed ‘up the chain’,

definitively prove strain relatedness.
Currently,
there
is
insufficient

with implications for the use of antimicrobials in
production animals and handling of carcasses

epidemiological
evidence
linking
the
consumption of contaminated food to

and meat processing. Public health messages
may best be targeted at the susceptible

increases of CA-CDI. Unlike other foodborne

population in the community, who may not

outbreaks, there are a number of factors that
may mediate the development of disease.

always be easily identified and who may not be
able to fully eliminate their risk through

Unlike salmonellosis or another equivalent

avoidance of potentially contaminated food.

The

presence

of

toxigenic

spores
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Another factor that needs to be taken into
consideration is variable testing methodologies

The potential for asymptomatic carriers of C.
difficile to shed the organism into the home
environment and cause disease in other
contacts has been demonstrated [148, 149],
although to date there has been no evidence
to support this route as a common mechanism
for disease transmission in the community [5].
This potential may be amplified in the case of
children under 2 years of age and their primary
carers; close contact with faecal matter as part of
caring for these children potentially exposes
carers to a higher level of spores as asymptotic
carriage in this group is high compared with
other healthy individuals [80, 82]. While the
role of asymptomatic carriers is not well
established, this is a plausible mechanism for
transmission in the community, and contact
with
potential
asymptomatic
carriers,
particularly young children, as a driver of
CA-CDI should be explored further.

across different countries and changes to more
sensitive testing methodologies over time [150].
The former may impact on the prevalence and,
at least partially, account for variable rates. The
latter

may

give

the

false

appearance

of

increasing rates, when the reality is just more
accurate detection methods. While evaluation
of individual laboratory methods used in all
studies was outside the scope of this review,
differences were noted across various studies,
which may account for
heterogeneity in the results.

some

of

the

Taking these limitations into account, it is
still apparent that CA-CDI is increasing, despite
almost certainly being underdiagnosed in the
community [49, 151]. Disease in the
community can be severe, with one study
showing CA-CDI cases were more likely to
develop severe infection than HA-CDI [152].
Further, there is evidence of increasing the
severity of disease among community cases,
using outcomes such as colectomy [153] as a

LIMITATIONS
There are several limitations when it comes to

measure. While hospital-based estimates vary
between facility and region, overall about

the interpretation of apparent increases in
CA-CDI in the international literature. An

one-third of CDI cases currently being
detected in outpatients appear to be CA-CDI.

increased
awareness
and
subsequent
ascertainment bias has been acknowledged as

CONCLUSION

a potential factor influencing the increase in
incidence [150]. It is logical that an increase in
profile among physicians would result in
increased testing
ascertainment. In

and subsequent case
order for individual

jurisdictions to monitor the impact of this
bias on reporting, the proportion of positive
cases should be reviewed alongside the raw
numbers of requested tests. These data allow
better interpretation of apparent increasing
rates.

There is evidence of a growing incidence of
CA-CDI worldwide, with cases in the community
resulting in severe disease. While ‘traditional’
risk factors for CDI are well established, cases in
the community lacking in traditional risk factors
are being documented, suggesting such cases
may have different risk factors for disease.
Importantly, there is a paucity of knowledge
around the epidemiology and risk factors for
CA-CDI on a global scale. The available evidence
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suggests

close

contacts,

the

environment,
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